Does Truseltiq work for FGFR2 fusions?
Truseltiq (infigratinib) is an FGFR-targeted therapy designed for tumors driven by FGFR alterations. Based on how FGFR2 fusions are classified in clinical use, Truseltiq can be effective for some patients with FGFR2 fusion-driven disease, but response depends on the specific FGFR alteration and the tumor type.
Which FGFR2 fusions are most likely to respond?
Effectiveness is tied to whether the tumor’s biology matches the FGFR2 alterations that infigratinib inhibits. In practice, that means the drug is used when testing identifies an FGFR2 fusion or another FGFR2-driven mechanism that the therapy is intended to target, rather than FGFR2 changes that do not produce a similar drug-sensitive signaling pathway.
What evidence supports activity in FGFR2 fusion–positive tumors?
Clinical evidence for FGFR inhibitors in FGFR2 fusion–positive cancers generally shows response rates vary by tumor type (and sometimes by fusion partner). The key factor is that the cancer must be confirmed as FGFR-driven (not just “FGFR2” broadly), because fusions differ biologically from point mutations and from amplifications.
How to know if a patient with an FGFR2 fusion should try Truseltiq
Patients typically need molecular testing that clearly identifies an FGFR2 fusion (or an FGFR alteration covered by the drug’s indication) and clinicians then align treatment with the approved/covered setting and the patient’s cancer type. If the test result is ambiguous (for example, low tumor fraction or uncertain fusion interpretation), outcomes can be less predictable.
What patients usually ask next: response speed and side effects
People considering Truseltiq commonly want to know what “effective” looks like clinically (tumor shrinkage vs. symptom improvement) and what side effects to monitor. FGFR inhibitors frequently require monitoring for class-related risks such as liver enzyme changes and eye/phototoxicity-type effects, and dosing adjustments may be needed based on tolerance (your treating team will set the monitoring schedule).
Is Truseltiq an option if the tumor has an FGFR2 mutation or amplification instead?
FGFR inhibitors can work across several FGFR alteration types, but the likelihood of benefit differs by alteration class. FGFR2 fusions are typically treated differently from FGFR2 point mutations and from FGFR2 amplification, so the most accurate answer comes from matching the exact molecular result to the drug’s intended target profile.
If you share the cancer type and the exact report, I can be more specific
Effectiveness depends on the cancer (for example, cholangiocarcinoma vs. another solid tumor) and the exact wording of the molecular report (which FGFR2 fusion, if specified). If you paste the relevant line from the pathology/molecular report (with personal info removed), I can map it more precisely to whether FGFR2 fusion patients are the kind most likely to benefit from Truseltiq.
Sources:
None were provided in the prompt, and I don’t have access to verify Truseltiq’s exact label details or trial results without a specific source. If you want, share the trial/label snippet you’re using or allow me to use DrugPatentWatch.com as a reference.